Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 4/20 | 0.49 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 7/20 | 0.43 |
| ▸ | NOS3 | P29474 | 6/20 | 0.43 |
| ▸ | NOS2 | P35228 | 6/20 | 0.43 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130655 | 0.89 | NOS2 (0.53) | IDH1NOS1NOS3NOS2CPB2 | |
| SCHEMBL13623090 | 0.79 | ASIC3 (0.48) | IDH1ASIC3NOS1NOS3NOS2 | |
| SCHEMBL3625374 | 0.78 | GABRA1 (0.44) | NOS1NOS3NOS2TLR7 | |
| SCHEMBL13615821 | 0.78 | IDH1 (0.43) | IDH1ASIC3NOS1NOS3NOS2 | |
| SCHEMBL13615819 | 0.78 | IDH1 (0.46) | IDH1ASIC3NOS1NOS3NOS2 | |
| SCHEMBL20402654 | 0.77 | KDM4E (0.57) | — | |
| SCHEMBL17615254 | 0.76 | NOS1 (0.46) | IDH1ASIC3NOS1NOS3NOS2 | |
| SCHEMBL3855209 | 0.76 | TRPV3 (0.54) | ASIC3TRPV3 | |
| SCHEMBL26788249 | 0.76 | TLR7 (0.32) | NOS1NOS3NOS2TLR7TRPV3 | |
| SCHEMBL10130883 | 0.76 | IDH1 (0.43) | IDH1ASIC3NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8383785-B2 | Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2009137737-A2 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6, 11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | IDH1 1333/4885ASIC3 1928/4885NOS1 3084/4885 |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | IDH1 1333/4885ASIC3 1928/4885NOS1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.